Relapse of severe neurosarcoidosis with switch from originator infliximab to biosimilar

There is increasing evidence that patients with neurosarcoidosis who respond incompletely to immunosuppression and corticosteroids do so with TNFα blockade.1,2 It appears that around 20% of those with severe CNS disease require treatment with TNFα antagonists; around 8% of those with neurosarcoidosis. Treatment is required for around 3 years; shorter courses often result in disease relapse at the same site.2